Potential role of transforming growth factor‐beta 1/Smad signaling in secondary lymphedema after cancer surgery. Issue 7 (9th June 2020)

• Record Type: Journal Article
• Authors: Sano, Masaki; Hirakawa, Satoshi; Suzuki, Minoru; Sakabe, Jun‐ichi; Ogawa, Mikako; Yamamoto, Seiji; Hiraide, Takanori; Sasaki, Takeshi; Yamamoto, Naoto; Inuzuka, Kazunori; Tanaka, Hiroki; Saito, Takaaki; Sugisawa, Ryota; Katahashi, Kazuto; Yata, Tatsuro; Kayama, Takafumi; Urano, Tetsumei; Tokura, Yoshiki; Sato, Kohji; Setou, Mitsutoshi; Takeuchi, Hiroya; Konno, Hiroyuki; Unno, Naoki
• Is Part Of: Cancer science. Volume 111:Issue 7(2020)
• Page Start: 2620
• Page End: 2634
• Publication Date: 2020-06-09
• Subjects: fibrosis -- lymphedema -- myofibroblasts -- pathology -- transforming growth factor‐beta; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14457
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Secondary lymphedema often develops after cancer surgery, and over 250 million patients suffer from this complication. A major symptom of secondary lymphedema is swelling with fibrosis, which lowers the patient's quality of life, even if cancer does not recur. Nonetheless, the pathophysiology of secondary lymphedema remains unclear, with therapeutic approaches limited to physical or surgical therapy. There is no effective pharmacological therapy for secondary lymphedema. Notably, the lack of animal models that accurately mimic human secondary lymphedema has hindered pathophysiological investigations of the disease. Here, we developed a novel rat hindlimb model of secondary lymphedema and showed that our rat model mimics human secondary lymphedema from early to late stages in terms of cell proliferation, lymphatic fluid accumulation, and skin fibrosis. Using our animal model, we investigated the disease progression and found that transforming growth factor‐beta 1 (TGFB1) was produced by macrophages in the acute phase and by fibroblasts in the chronic phase of the disease. TGFB1 promoted the transition of fibroblasts into myofibroblasts and accelerated collagen synthesis, resulting in fibrosis, which further indicates that myofibroblasts and TGFB1/Smad signaling play key roles in fibrotic diseases. Furthermore, the presence of myofibroblasts in skin samples from lymphedema patients after cancer surgery emphasizes the role of these cells in promoting fibrosis. Suppression of myofibroblast‐dependent TGFB1 production may therefore represent an effective pharmacological treatment for inhibiting skin fibrosis in human secondary lymphedema after cancer surgery. Abstract : Secondary lymphedema develops and causes skin fibrosis after cancer surgery. We developed a novel rat hindlimb model that accurately mimics human secondary lymphedema, and investigated disease progression. We found that myofibroblasts and transforming growth factor‐beta 1/Smad signaling play key roles in the skin fibrosis of secondary lymphedema.